Conclusion

Diabetic retinopathy remains the leading cause of blindness among working-aged adults around the world. The prevalence of DM is increasing in the world, notably in Asia, and the incidence of VTDR is increasing. Duration of diabetes, poor glycemic control, and hypertension are the major risk factors for developing DR. The pathophysiology of DR is multifactorial and complex. Currently, tight glycemic control may be the best way to reduce the incidence and progression of DR.

References

1. Zhang X, Saaddine JB, Chou CF et al (2010) Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 304:649–656

2. Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in United States [article online]. Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed 1 May 2013

3.Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564

4. Fong DS, Aiello L, Gardner TW et al (2003) Diabetic retinopathy. Diabetes Care 26:226–229 5. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for

2010 and 2030. Diabetes Res Clin Pract 87:4–14

6. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321

7. Chan JC, Malik V, Jia W et al (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:2129–2140

8. Wang FH, Liang YB, Zhang F et al (2009) Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology 116:461–467

9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520–526

10. Roy MS, Klein R, O'Colmain BJ, Klein BE, Moss SE, Kempen JH (2004) The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol 122:546–551

11.Wong TY, Mwamburi M, Klein R et al (2009) Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 32:2307–2313

12. Zheng Y, He M, Congdon N (2012) The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol 60:428–431

13. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE (2008) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115:1859–1868

14. Tapp RJ, Shaw JE, Harper CA et al (2003) The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 26:1731–1737

15. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124–136

16. Todd JA, Walker NM, Cooper JD et al (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39:857–864

17. Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885

18. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053

19. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527–532

20. American Diabetes Association (2010) Standards of medical care in diabetes—2010. Diabetes Care 33(Suppl 1):S11–S61 [erratum in Diabetes Care 2010;33:692]

21. American Diabetes Association (2002) Diabetic retinopathy. Diabetes Care 25(Suppl 1):s90– s93. Available from http://care.diabetesjournals.org/content/25/suppl_1/s90.full. Accessed 1 May 2013

22. Henricsson M, Nystrom L, Blohme G et al (2003) The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26:349–354

23. Klein R, Klein BE, Moss SE, Cruickshanks KJ (1994) The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 112:1217–1228

24. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group (1993) N Engl J Med 329:977–986

25.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group (1998) BMJ 317:703–713

26. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group (1998) Lancet 352:837–853

27. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group (1998) Lancet 352:854–865

28. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes (2009) Diabetes Care 32:1327–1334

29. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K (2011) Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 34:145–150

30. Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163

31. Klein RKB, Moss SE, Davis MD, DeMets DL (1988) Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260:2864–2871

32. Tsugawa Y, Takahashi O, Meigs JB et al (2012) New diabetes diagnostic threshold of hemoglobin A(1c) and the 3-year incidence of retinopathy. Diabetes 61:3280–3284

33. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial (1995) Diabetes 44:968–983

34. Esteves J, da Rosa CM, Kramer CK, Osowski LE, Milano S, Canani LH (2009) Absence of diabetic retinopathy in a patient who has had diabetes mellitus for 69 years, and inadequate glycemic control: case presentation. Diabetol Metab Syndr 1:13

35. Mima A, Qi W, Hiraoka-Yamomoto J et al (2012) Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes. Invest Ophthalmol Vis Sci 53:8424–8432

36. Rani PK, Raman R, Chandrakantan A, Pal SS, Perumal GM, Sharma T (2009) Risk factors for diabetic retinopathy in self-reported rural population with diabetes. J Postgrad Med 55: 92–96

37. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565–1576

38. Mohamed IN, Soliman SA, Alhusban A et al (2012) Diabetes exacerbates retinal oxidative stress, inflammation, and microvascular degeneration in spontaneously hypertensive rats. Mol Vis 18:1457–1466

39. Rassam SM, Patel V, Kohner EM (1995) The effect of experimental hypertension on retinal vascular autoregulation in humans: a mechanism for the progression of diabetic retinopathy. Exp Physiol 80:53–68

40. Marshall G, Garg SK, Jackson WE, Holmes DL, Chase HP (1993) Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 100:1133–1139

41. Danser AH, van den Dorpel MA, Deinum J et al (1989) Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 68:160–167

42. Williams B, Baker AQ, Gallacher B, Lodwick D (1995) Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25:913–917

43. Stolk RP, van Schooneveld MJ, Cruickshank JK et al (2008) Retinal vascular lesions in patients of Caucasian and Asian origin with type 2 diabetes: baseline results from the ADVANCE Retinal Measurements (AdRem) study. Diabetes Care 31:708–713

44. Haffner SM, Fong D, Stern MP et al (1988) Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes 37:878–884

45. Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J (1989) Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. San Luis Valley Diabetes Study. Diabetes 38:1231–1237

46. Abhary S, Hewitt AW, Burdon KP, Craig JE (2009) A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 58:2137–2147

47. Haffner SM, Mitchell BD, Moss SE et al (1993) Is there an ethnic difference in the effect of risk factors for diabetic retinopathy? Ann Epidemiol 3:2–8

48. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J (2012) Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol 57:347–370

49. Tong Z, Yang Z, Patel S et al (2008) Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A 105:6998–7003

50.Zietz B, Buechler C, Kobuch K, Neumeier M, Scholmerich J, Schaffler A (2008) Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes 116: 532–536

51. Chaturvedi N, Sjoelie AK, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289

52. Ballard DJ, Melton LJ 3rd, Dwyer MS et al (1986) Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care 9:334–342

53. Dirani M, Xie J, Fenwick E et al (2011) Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci 52:4416–4421

54. Klein R, Klein BE, Moss SE (1997) Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 157:650–656

55. Mancini JE, Ortiz G, Croxatto JO, Gallo JE (2013) Retinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat-diet. BMC Ophthalmol 13:14

56. Chew EY, Ambrosius WT, Davis MD et al (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363:233–244

57. Keech AC, Mitchell P, Summanen PA et al (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:1687–1697

58. Bordet R, Ouk T, Petrault O et al (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34:1341–1346

59. Chen Y, Hu Y, Lin M et al (2013) Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 62:261–272

60. Meissner M, Stein M, Urbich C et al (2004) PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 94:324–332

61.Yokoyama Y, Xin B, Shigeto T et al (2007) Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 6:1379–1386

62. Ramachandran A, Snehalatha C, Vijay V, King H (2002) Impact of poverty on the prevalence of diabetes and its complications in urban southern India. Diabet Med 19:130–135

63. Hirsch IB, Brownlee M (2010) Beyond hemoglobin A1c–need for additional markers of risk for diabetic microvascular complications. JAMA 303:2291–2292

64. Klein R (2008) The epidemiology of diabetic retinopathy. In: Duh E (ed) Diabetic retinopathy. Humana, New York, NY, pp 67–107

65. Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366:1227–1239

66. West SD, Groves DC, Lipinski HJ et al (2010) The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea. Diabet Med 27:423–430

67. Targher G, Bertolini L, Chonchol M et al (2010) Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 53:1341–1348

68. Arnold E, Rivera JC, Thebault S et al (2010) High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes 59:3192–3197

69. Nguyen TT, Alibrahim E, Islam FM et al (2009) Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care 32:1704–1709

70. Kowluru RA, Engerman RL, Case GL, Kern TS (2001) Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 38:385–390

71. Brucklacher RM, Patel KM, VanGuilder HD et al (2008) Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med Genomics 1:26

72. Singh PP, Mahadi F, Roy A, Sharma P (2009) Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2. Indian J Clin Biochem 24:324–342

73. Bhagat N, Grigorian RA, Tutela A, Zarbin MA (2009) Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 54:1–32

74. Betteridge DJ (2000) What is oxidative stress? Metabolism 49:3–8

75. Kowluru R, Kern TS, Engerman RL (1994) Abnormalities of retinal metabolism in diabetes or galactosemia. II. Comparison of gamma-glutamyl transpeptidase in retina and cerebral cortex, and effects of antioxidant therapy. Curr Eye Res 13:891–896

76. Metea MR, Newman EA (2007) Signalling within the neurovascular unit in the mammalian retina. Exp Physiol 92:635–640

77. Kankova K, Marova I, Zahejsky J et al (2001) Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism 50:1152–1160

78. Hudson BI, Hofmann M, Bucciarelli L, Wendt T, Moser B, Lu Y, Qu W, Stern D, D’Agati V, Yan SD et al (2002) Glycation and diabetes: the RAGE connection. Curr Sci 83:1515–1521. Accessed at http://www.iisc.ernet.in/currsci/dec252002/1515.pdf

79. Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL (2008) Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 34:392–395

80. Abcouwer SF, Antonetti DA (2013) A role for systemic inflammation in diabetic retinopathy. Invest Ophthalmol Vis Sci 54:2384

81. Arita R, Nakao S, Kita T et al (2013) A Key Role for ROCK in TNF-alpha-Mediated Diabetic Microvascular Damage. Invest Ophthalmol Vis Sci 54:2373–2383

82. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S (2006) Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 20:1366–1369

83. Doganay S, Evereklioglu C, Er H et al (2002) Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 16:163–170

84. Joussen AM, Poulaki V, Mitsiades N et al (2002) Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16:438–440

85. Lieth E, LaNoue KF, Antonetti DA, Ratz M (2000) Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. The Penn State Retina Research Group. Exp Eye Res 70:723–730

86. Barber AJ, Gardner TW, Abcouwer SF (2011) The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci 52:1156–1163

87. Ng YK, Zeng XX, Ling EA (2004) Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats. Brain Res 1018:66–72

88. van Dijk HW, Kok PH, Garvin M et al (2009) Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 50:3404–3409

89. van Dijk HW, Verbraak FD, Kok PH et al (2010) Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci 51:3660–3665

90. Lopes de Faria JM, Russ H, Costa VP (2002) Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br J Ophthalmol 86:725–728

91. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P (2005) Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest Ophthalmol Vis Sci 46:349–357

92. Chan PS, Kanwar M, Kowluru RA (2010) Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J Diabetes Complications 24:55–63